Form 8-K - Current report:
SEC Accession No. 0001213900-25-060366
Filing Date
2025-07-01
Accepted
2025-07-01 16:05:48
Documents
14
Period of Report
2025-06-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0247668-8k_allarity.htm   iXBRL 8-K 26927
2 PRESS RELEASE, DATED JUNE 30, 2025. ea024766801ex99-1_allarity.htm EX-99.1 12289
3 GRAPHIC ex99-1_001.jpg GRAPHIC 18474
  Complete submission text file 0001213900-25-060366.txt   234950

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE allr-20250630.xsd EX-101.SCH 3014
5 XBRL LABEL FILE allr-20250630_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE allr-20250630_pre.xml EX-101.PRE 22358
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0247668-8k_allarity_htm.xml XML 3687
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 251096338
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)